1479 related articles for article (PubMed ID: 33031522)
1. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522
[TBL] [Abstract][Full Text] [Related]
2. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
[TBL] [Abstract][Full Text] [Related]
4. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials.
Gong C; Shen SC; Zhang K; Zhou L; Shen JJ; Zhao JY; Ding SG; Ma LK; Gao H
Front Cardiovasc Med; 2022; 9():926979. PubMed ID: 36312269
[TBL] [Abstract][Full Text] [Related]
5. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
7. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
Qiu M; Ding L; Zhou H
Medicine (Baltimore); 2021 Mar; 100(10):e25121. PubMed ID: 33725910
[TBL] [Abstract][Full Text] [Related]
8. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
9. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
Sacre JW; Magliano DJ; Shaw JE
Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
[TBL] [Abstract][Full Text] [Related]
12. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
Corbin KD; Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Frederich R; Liu J; Pong A; Lin J; Cater NB; Pratley RE
Diabetes Obes Metab; 2023 Mar; 25(3):758-766. PubMed ID: 36394384
[TBL] [Abstract][Full Text] [Related]
13. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
[TBL] [Abstract][Full Text] [Related]
14. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
Chang R; Liu SY; Zhao LM
Medicine (Baltimore); 2021 Nov; 100(47):e27802. PubMed ID: 34964748
[TBL] [Abstract][Full Text] [Related]
15. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
[TBL] [Abstract][Full Text] [Related]
16. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
17. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
;
Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
[TBL] [Abstract][Full Text] [Related]
18. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM; Kang YM; Im K; Neuen BL; Anker SD; Bhatt DL; Butler J; Cherney DZI; Claggett BL; Fletcher RA; Herrington WG; Inzucchi SE; Jardine MJ; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Solomon SD; Staplin N; Vaduganathan M; Wanner C; Wheeler DC; Zannad F; Zhao Y; Heerspink HJL; Sabatine MS; Wiviott SD
Circulation; 2024 Jun; 149(23):1789-1801. PubMed ID: 38583093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
